LX-2343
|
|
- CAS号:
- 333745-53-2
- 英文名:
- LX-2343
- 英文别名:
- LX-2343;LX2343;LX-2343;LX 2343;2-[N-(Benzenesulfonyl)-5-chloro-2-methoxyanilino]-N-(1,3-benzodioxol-5-yl)acetamide;Acetamide, N-1,3-benzodioxol-5-yl-2-[(5-chloro-2-methoxyphenyl)(phenylsulfonyl)amino]-;N-(Benzo[d][1,3]dioxol-5-yl)-2-(N-(5-chloro-2-methoxyphenyl)phenylsulfonamido)acetamide;Autophagy,PI3K,Amyloid-β,Inhibitor,β-Secretase,Beta-secretase,LX-2343,LX2343,inhibit,BACE,Phosphoinositide 3-kinase,β-amyloid peptide,LX 2343,Abeta
- 中文名:
- LX-2343
- 中文别名:
- 化合物LX2343;LX-2343,BACE1酶抑制剂;N-(苯并[D][1,3]二氧戊环-5-基)-2-(N-(5-氯-2-甲氧基苯基)苯基磺酰胺基)乙酰胺
- CBNumber:
- CB63374896
- 分子式:
- C22H19ClN2O6S
- 分子量:
- 474.91
- MOL File:
- 333745-53-2.mol
|
|
|
LX-2343化学性质
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO:73.33(Max Conc. mg/mL);154.41(Max Conc. mM)
DMF:33.0(Max Conc. mg/mL);69.49(Max Conc. mM)-
|
-
形态:
-
A solid
-
|
-
颜色:
-
White to off-white
-
|
LX-2343性质、用途与生产工艺
LX2343是一种多靶点试剂,能够有效地减缓阿尔茨海默发病过程中多种异常指标。它是BACE1抑制剂,IC50为11.43±0.36 μM。
BACE1
11.43 μM (IC
50
)
|
PI3K
15.99 μM (IC
50
)
|
Aβ
|
Autophagy
|
LX2343 (5-20 μM) dose-dependently decreased Aβ accumulation in HEK293-APPsw and CHO-APP cells, and promotes Aβ clearance in SH-SY5Y cells and primary astrocytes. LX2343 ameliorates cognitive dysfunction in APP/PS1 transgenic mice via both Aβ production inhibition and clearance promotion, which highlights the potential of LX2343 in the treatment of AD. Western blot results in both HEK293-APP
sw
cells and CHO-APP cells demonstrate that LX2343 fails to regulate BACE1 protein levels, while in vitro BACE1 enzymatic activity assays indicated that LX2343 dose-dependently decreases BACE1 activity (TDC as a positive control) with an IC
50
of 11.43±0.36 μM. To test whether competition exists between LX2343 and ATP, we investigated the effects of ATP at different concentrations on the inhibitory activity of LX2343. The result demonstrated that the inhibition of LX2343 against PI3K is virtually unaffected by ATP. Thus, this result suggested that LX2343 is a non-ATP competitive inhibitor of PI3K. In the presence of 10 μM of ATP, the IC
50
of LX2343 is 13.11±1.47 μM, in the presence of 50 μM ATP, the IC
50
of LX2343 is 13.86±1.12 μM, in the presence of 100 μM ATP, the IC
50
of LX2343 is 15.99±3.23 μM .
APP/PS1 mice express chimeric human Swedish mutant APP and a mutant human presenilin 1 protein and are widely used as an effective animal model for AD dementia. The amelioration of memory impairment by LX2343 is evaluated t in this model using the MWM test. In 8-d training trials, the path lengths and escape latencies used to find the platform for APP/PS1 transgenic mice are remarkably longer than those for non-transgenic mice, while 10 mg/kg LX2343 administration obviously antagonizes the prolonged path lengths and escape latencies at d 7 and 8. In the probe trial assay, the LX2343-administered transgenic mice cross over the hidden location of the platform more frequently compared with the vehicle-administered transgenic mice.
LX-2343
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/08/19 | HY-111383 | LX-2343 LX2343 | 333745-53-2 | 5mg | 950元 |
2024/08/19 | HY-111383 | LX-2343 LX2343 | 333745-53-2 | 10mM * 1mLin DMSO | 990元 |
333745-53-2, LX-2343 相关搜索:
- 药靶配体
- LX-2343,BACE1酶抑制剂
- N-(苯并[D][1,3]二氧戊环-5-基)-2-(N-(5-氯-2-甲氧基苯基)苯基磺酰胺基)乙酰胺
- 化合物LX2343
- 333745-53-2
- N-(Benzo[d][1,3]dioxol-5-yl)-2-(N-(5-chloro-2-methoxyphenyl)phenylsulfonamido)acetamide
- Autophagy,PI3K,Amyloid-β,Inhibitor,β-Secretase,Beta-secretase,LX-2343,LX2343,inhibit,BACE,Phosphoinositide 3-kinase,β-amyloid peptide,LX 2343,Abeta
- 2-[N-(Benzenesulfonyl)-5-chloro-2-methoxyanilino]-N-(1,3-benzodioxol-5-yl)acetamide
- Acetamide, N-1,3-benzodioxol-5-yl-2-[(5-chloro-2-methoxyphenyl)(phenylsulfonyl)amino]-
- LX2343;LX-2343;LX 2343
- LX-2343